Telix Pharmaceuticals (ASX:TLX) has raised its full-year revenue guidance to between US$800 million and US$820 million following a solid third quarter marked by 53 per cent year-on-year revenue growth, reimbursement wins for Gozellix in the United States, and further expansion of its commercial footprint in Europe. …
Telix Pharmaceuticals lifts revenue guidance after strong third quarter performance
October 15, 2025 Australian Biotech
Latest Video
New Stories
-
Proteomics International secures WA Government grant to advance world-first blood test for endometriosis
November 9, 2025 - - Australian Biotech -
AVITA Medical narrows losses and secures EU approval as reimbursement challenges ease
November 9, 2025 - - Australian Biotech -
From potential to practice - AI Health Summit to focus on adoption, implementation and governance
November 9, 2025 - - Latest News -
Call for national action to lift immunisation rates as whooping cough spread worsens
November 9, 2025 - - Latest News -
Pharmacy Guild - 'You can’t fragment care you’re not receiving'
November 8, 2025 - - Latest News -
The 'Dispatched' Week in Review' Podcast - 7 November
November 7, 2025 - - Podcast -
Donald Trump announces 'MFN' deals with Lilly and Novo Nordisk and end to 'global freeloading'
November 7, 2025 - - Latest News